Evaluation of the Donepezil and Rivastigmine co – administration on the cognitive deficits induced by EcT: A Randomized Double Blind Clinical Trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20171229038124N1

Enrollment

Registered

2018-08-04

Start date

2017-11-22

Completion date

Unknown

Last updated

2018-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

EcT in patients with Mood Disorders. Bipolar affective disorder

Interventions

Intervention 1: Intervention group: Tablet Donepezil 5 mg daily for 2 weeks. Intervention 2: Intervention group: Cap Rivastigmine 1.5 mg twice a day for one week and 3 mg twice a day until the end of

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Schizophrenia Disorder Schizoaffective Disorder Bipolar Mood Disorder Major Depressive Disorder ECT 6-12 Sessions

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Evaluation of cognitive function by MMSE. Timepoint: In the first, middle and end of the period of ECT Therapy. Method of measurement: MMSE.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMasoumeh Nazarinasab

Ahvaz University of Medical Sciences

Nazarinasab-m@ajums.ac.ir+98 61337430011

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026